| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Biomarin Pharmaceutical Inc.'s insiders have reduced their positions by a net 17,557 shares worth roughly $1.2M.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 214.6K | $11.95M | - | |
| CFO | 123.3K | $6.86M | - | |
| VP | 84.1K | $4.68M | - | |
| VP | 61.0K | $3.40M | - | |
| Dir | 49.4K | $2.75M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2016 | George Eric Davis65 | EVP, General Counsel | Sell | 2,167 | $100.00 | $216,700.00 | -3.0% | |
| Aug 1, 2016 | Brian Mueller64 | VP, Corporate Controller | Sell | 287 | $100.00 | $28,700.00 | -2.0% | |
| Jul 27, 2016 | V Bryan Lawlis53 | Director | Sale+OE | 1,100 | $95.39 | $104,926.80 | -7.4% | |
| Jul 22, 2016 | V Bryan Lawlis53 | Director | Sale+OE | 6,400 | $95.01 | $608,064.00 | -31.6% | |
| Jul 18, 2016 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 41,666 | $92.72 | $3,863,271.52 | -9.9% | |
| Jul 7, 2016 | George Eric Davis65 | EVP, General Counsel | Sell | 2,167 | $90.00 | $195,030.00 | -3.0% | |
| Jun 20, 2016 | V Bryan Lawlis53 | Director | Sell | 550 | $82.77 | $45,523.50 | -3.8% | |
| Jun 16, 2016 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 41,666 | $80.55 | $3,356,196.30 | -9.9% | |
| Jun 6, 2016 | Daniel K Spiegelman59 | EVP, Chief Financial Officer | Sell | 1,649 | $89.14 | $146,991.86 | -3.4% | |
| May 31, 2016 | Daniel K Spiegelman59 | EVP, Chief Financial Officer | Sale+OE | 20,841 | $89.88 | $1,873,125.75 | -29.3% |